Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714713 · ClinicalTrials.gov registry record · Phase 3
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Phase 3 study, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 830
- Enrollment target
NCT01714713: Completed Phase 3 study, sponsored by FORUM Pharmaceuticals.
NCT01714713 is a Phase 3 study that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 830 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714713, a Phase 3 study, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 830 participants
- Enrollment target
Study Summary
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.
Primary Outcome
All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG, and laboratory tests (hematology/blood/chemistry/urinalysis)
Interventions
- DRUG EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
What the finished NCT01714713 record still lists
NCT01714713 is an interventional study that assigns participants to a tested intervention. The registered 830 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which EVP-6124 is the first listed.
NCT01714713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01714713 about?
NCT01714713 is a clinical study titled "A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy". This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.
What is the current status of trial NCT01714713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 830 participants. The study started on 2013-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01714713?
The interventions under investigation include: EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01714713?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01714713's enrollment target sits among peer trials
830 398th of 2000 higher than 1,601 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT06910553 · 832 participants
IBD Pregnancy Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia